Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has assisted Peab in connection with a transaction with SkiStar
Mandate

Vinge has assisted Peab in connection with a transaction with SkiStar

May 28, 2021 Capital Markets and Public M&A Real Estate and Construction

Vinge has assisted Peab in connection with a transaction with Skistar, whereby Peab and SkiStar deepen the collaboration on management and development of properties in the Scandinavian mountains.

Through the transaction, three jointly owned lodges in the Swedish and Norwegian mountainside locations are transferred to the same group structure and in addition, the joint ventures will acquire three new lodges in Hemsedal in Norway, Lindvallen in Sälen and Hundfjället in Sälen (under construction) and development rights for around 60,000 GFA in Sälen, Vemdalen, Åre and Duved. In addition, in connection with the transaction, SkiStar is to sign new leases on both the newly acquired properties and the previously jointly owned properties.

Vinge’s team consisted of Charlotte Levin, Assur Badur, Kristoffer Larson and Joel Magnusson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024